Skip to content
Dosage GuideResearch Reference

Lanreotide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Lanreotide. All information is for educational purposes only.

Quick Answer

Lanreotide (Somatuline Depot) is administered via deep subcutaneous injection, typically every 28 days. Dosage adjustments are based on individual biochemical response and tolerability. For acromegaly, initial doses range from 60-120 mg, while NETs often start at 120 mg. Some patients may extend dosing intervals to every 6-8 weeks if disease control is maintained.

→ Lanreotide Benefits→ Lanreotide Side Effects→ Full Lanreotide Profile
Table of Contents

Standard Dosage Range

Research dosing range: 60–120 mg every 28 days (standard); up to 120 mg every 14 days (aggressive)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Acromegaly

60–120 mgEvery 28 days
Duration

Ongoing (maintenance)

Initial dose is often 90 mg every 28 days. Titrate based on IGF-1 and GH levels. Some patients can be managed on 60 mg every 28 days, while others may need 120 mg.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

120 mgEvery 28 days
Duration

Ongoing (maintenance)

The standard dose in the CLARINET trial was 120 mg every 28 days. Dosing adjustments are less common in NETs compared to acromegaly.

Carcinoid Syndrome (Symptom Control)

60–120 mgEvery 28 days
Duration

Ongoing (maintenance)

Dose titrated based on symptom control (flushing, diarrhea). May require higher doses initially, then adjusted downward for maintenance.

Advanced Renal Cell Carcinoma (in combination with everolimus)

120 mgEvery 28 days
Duration

Until disease progression or unacceptable toxicity

Used in combination with everolimus for patients who have progressed on VEGF-targeted therapy.

Timing & Frequency

Lanreotide is administered as a deep subcutaneous injection, typically in the upper outer quadrant of the buttock, alternating injection sites each month. It should be administered at the same time each month, ideally by a healthcare professional for the initial doses, although patients can be trained for self-administration.

Cycle Guidance

Lanreotide is generally administered chronically for long-term management of acromegaly, NETs, and carcinoid syndrome. Discontinuation may lead to recurrence of symptoms or disease progression. Dose adjustments are made based on biochemical markers and symptom control, rather than cycling on and off the medication.

Reconstitution Reference

Quick reference for reconstituting Lanreotide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizePrefilled syringe containing a supersaturated solution
BAC Water VolumeN/A (prefilled syringe)
Concentration & DrawVaries depending on the specific formulation (60 mg, 90 mg, or 120 mg)
StorageStore refrigerated at 2–8°C (36–46°F). Protect from light.
StabilityStable until expiration date when stored as directed.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical starting dose for acromegaly?
The typical starting dose for lanreotide in acromegaly is 90 mg administered every 28 days. This dose may be adjusted based on IGF-1 and GH levels.
Can I self-administer lanreotide?
Yes, lanreotide (Somatuline Autogel) is designed for self-administration via deep subcutaneous injection. However, it is crucial to receive proper training from a healthcare professional before attempting self-injection.
How long does it take to see results from lanreotide?
The onset of action varies depending on the indication. For acromegaly, it may take several weeks to months to see a significant reduction in IGF-1 levels. For carcinoid syndrome, symptom control may be observed within a few weeks.
What if I miss a dose of lanreotide?
If you miss a dose of lanreotide, contact your healthcare provider for instructions. Do not double the next dose to make up for the missed dose.

Last updated: 2026-02-19